Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy save search
Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022 Regulatory News: Lysogene announced that it will host...
Published: 2022-11-18 (Crawled : 09:00) - biospace.com/
RAPT | $8.54 -7.07% -7.61% 620K
|
Health Technology
|
| O: -7.32%
H: 1.16%
C: -7.7%
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
|
| O: 46.45%
H: 16.3%
C: -6.17%
GTHX | $4.31 -5.28% -5.57% 670K
|
Health Technology
|
| O: -23.86%
H: 2.92%
C: -0.61%
topline therapy results study
Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease
Published: 2021-04-13 (Crawled : 15:00) - biospace.com/
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
|
| O: 32.23%
H: 2.4%
C: -20.0%
disease alzheimer positive results positive therapy results lomecel-b alzheimer’s alzheimer's disease t-cell alzheimer's
Longeveron to Participate in Phacilitate Advanced Therapies Week
Published: 2022-01-25 (Crawled : 13:30) - globenewswire.com
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
|
| O: -3.28%
H: 24.38%
C: 9.1%
therapy
Longeveron to Participate in Phacilitate Advanced Therapies WeekLongeveron management will present live in multiple sessions at the Advanced Therapies Week at the Miami Beach Convention Center
Published: 2022-01-25 (Crawled : 14:30) - biospace.com/
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
|
| O: -3.28%
H: 24.38%
C: 9.1%
therapy
Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy
Published: 2021-09-13 (Crawled : 18:00) - biospace.com/
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
|
| O: 1.88%
H: 0.0%
C: -3.16%
therapy response
R&D Efforts for Alzheimer's Therapies on the Rise with over 120 Drugs in Development
Published: 2022-03-31 (Crawled : 13:20) - prnewswire.com
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
|
| O: 39.73%
H: 51.65%
C: 46.96%
MESO | $5.17 -3.72% -3.47% 290K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: -2.09%
DNLI | $17.84 -2.3% -2.3% 990K
|
Health Technology
|
| O: 4.91%
H: 0.0%
C: -5.35%
SAVA | $20.01 -12.04% -13.66% 2M
|
Health Technology
|
| O: 0.34%
H: 1.24%
C: -3.96%
ALEC | $5.64 -6.31% -6.74% 380K
|
Health Technology
|
| O: 0.48%
H: 1.72%
C: -2.2%
drug therapy alzheimer's alzheimer’s
Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker
Published: 2022-08-25 (Crawled : 12:00) - globenewswire.com
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
|
| O: 2.12%
H: 6.4%
C: -0.19%
patent grant biomarker therapy
Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical OfficerExperienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs
Published: 2023-07-11 (Crawled : 15:00) - biospace.com/
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
|
| O: 0.95%
H: 5.35%
C: 3.14%
pharma medical therapy
Organovo Highlights FXR314 Combination Therapy Potential and Plan
Published: 2023-11-08 (Crawled : 13:00) - globenewswire.com
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
|
| O: 2.45%
H: 1.06%
C: -7.45%
fxr314 potential therapy
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
|
| O: 0.0%
H: 6.67%
C: 5.93%
fxr314 potential therapy
USD 2.05 billion growth in the Photodynamic Therapy Market from 2022 to 2027, highlighting major innovations and key vendor offerings- Reported by Technavio
Published: 2024-02-16 (Crawled : 13:30) - prnewswire.com
SNGX | $0.47 21.73% 17.38% 130M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: -5.62%
key therapy growth market
Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract Regarding Patient Outcomes Associated with Cancer Therapy-Related Diarrhea Accepted for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting
Published: 2021-04-29 (Crawled : 12:15) - jaguarhealth.gcs-web.com
JAGX | $0.1188 31.56% 17.16% 110M
|
Health Technology
|
| O: -4.22%
H: 5.03%
C: -4.4%
presentation tcom diarrhea therapy cancer
Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs
Published: 2021-05-18 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1188 31.56% 17.16% 110M
|
Health Technology
|
| O: 0.0%
H: 4.07%
C: 0.81%
diarrhea therapy crofelemer
Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company’s Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
JAGX | $0.1188 31.56% 17.16% 110M
|
Health Technology
|
| O: -5.69%
H: 0.0%
C: 0.0%
ongoing trial diarrhea therapy cancer phase 3 breast cancer symposium
Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea
Published: 2021-12-10 (Crawled : 15:00) - biospace.com/
JAGX | $0.1188 31.56% 17.16% 110M
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: 0.0%
health phase 2 presentation diarrhea therapy initiated crofelemer
Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Published: 2021-11-19 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.1188 31.56% 17.16% 110M
|
Health Technology
|
| O: 1.72%
H: 6.44%
C: 2.37%
phase 2 diarrhea therapy results cancer topline breast cancer initiated crofelemer
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2022-01-04 (Crawled : 01:00) - biospace.com/
JAGX | $0.1188 31.56% 17.16% 110M
|
Health Technology
|
| O: 3.74%
H: 0.0%
C: 0.0%
treatment health diarrhea therapy crofelemer
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
Published: 2021-12-21 (Crawled : 20:20) - jaguarhealth.gcs-web.com
JAGX | $0.1188 31.56% 17.16% 110M
|
Health Technology
|
| O: -7.25%
H: 3.91%
C: -7.81%
treatment fda health approval diarrhea therapy crofelemer
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
Published: 2022-01-12 (Crawled : 16:20) - jaguarhealth.gcs-web.com
FNCTF | $11.128 -0.29% -20.84% 0
|
Communications
|
| O: 0.0%
H: 0.0%
C: 0.0%
JAGX | $0.1188 31.56% 17.16% 110M
|
Health Technology
|
| O: 12.9%
H: 0.0%
C: 0.0%
veterinarians treatment health conference diarrhea therapy
Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
Published: 2021-12-10 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.1188 31.56% 17.16% 110M
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: 0.0%
health phase 2 symposium sabcs presentation diarrhea therapy cancer breast cancer initiated crofelemer
Gainers vs Losers
| 46% | 54% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.